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VA, USA.
Background: Recently, heteromeric GPCR complexes have become attractive
targets for drug development since they exhibit distinct signaling and
cell-specific localization from their homomeric counterparts. Yet, the effect
of heteromerization on the pharmacology of many GPCR homomers remains
unknown. We have undertaken the task to examine the effect of heteromeriza-
tion on Gs signaling through the adenosine 2A receptor (A2AR) and Gi signaling
through the dopamine receptor type 2 (D2R) because the A2AR-D2R heteromer
is an emerging therapeutic target for Parkinson’s disease. Previous work sug-
gests A2AR-D2R heteromerization induces reciprocal antagonism of homo-
meric signaling.
Methods:We examined the effect of heteromerization onA2AR andD2R homo-
meric signaling using electrophysiology and the Xenopus oocyte heterologous
expression system. GIRK channels were used as reporters for Gi signaling
because activation leads to direct Gbeta-gamma-mediated stimulation of the
GIRK current.We also coupled GIRK channels to Gs signaling by over express-
ingGas. Our electrophysiological assay is innovative because it allows us to opti-
mize the conditions of heteromerization. We anticipate that specific ligand
combinations targeting the A2AR-D2R heteromer will be more efficacious than
individual drug administration targeting A2AR or D2R homomers.
Results: Preliminary data have demonstrated that heteromer formation
decreases dopamine-elicited Gi signaling through the D2R and CGS-21680-
elicited Gs signaling through the A2AR. Furthermore, this reciprocal antago-
nism seemed to occur through a wide GPCR (cRNA) injection ratio. Currently,
we are examining crosstalk by assessing whether A2AR agonists or inverse
agonists will decrease or increase D2R-mediated Gi signaling through the
A2AR-D2R heteromer. Modulation of Gs signaling through the A2AR by D2R
ligands is also being examined.
Conclusions: Our electrophysiological assay demonstrates A2AR-D2R hetero-
merization induces reciprocal antagonism reducing both A2AR and D2R
signaling from that of homomeric levels.
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The dopamine D2-like receptors (D2R, D3R, and D4R), which belong to class A
Gprotein-coupled receptors, are important targets for antipsychotics. In the devel-
opment of novel antipsychotics to avoid adverse side effects, subtype-selective
dopamine receptor ligands that bind divergent secondary binding pockets
(SBP) in addition to the conserved orthosteric binding site (OBS) have been
discovered. SB269652, an allosteric modulator of D2R, consists of a tetrahydroi-
soquinoline pharmacophore bound in the OBS and an indole-2-carboxamide
moiety bound in a SBP between TM2 and TM7. This ligand was recently charac-
terized to act allosterically by a novel mechanism involving a D2R homodimer
whereby the bitopic bindingmode of SB269652 in one protomer negativelymod-
ulates the binding of an orthosteric ligand, either an agonist or an inverse agonist,
to the second protomer (Lane et al., Nature Chemical Biology, 2014).
To characterize the structural basis for the allosteric effect of SB269652,
we combined ligand modifications, complementary receptor mutagenesis, and
computational analysis, to identify the key interactions between SB269652
and D2R and the correspondingly induced conformational changes that are crit-
ical to propagate the allosteric impact across the dimer interface.We specifically
considered three pairs of SB269652 derivatives that are modified in the orthos-
teric or secondary pharmacophore, or the linker region - in each pair, the modi-
fications either retain/improve or eliminate the allosteric property. Using
molecular docking and dynamics simulations, we characterized the binding
modes of these derivatives in D2R, either in a protomer alone or in a dimer
context with an orthosteric ligand bound in the other protomer. The results of
our comparative modeling and analysis highlight the importance of thereceptor-ligand interaction formed in the SBP between Glu95(2.65) and the
indole-2-carboxamide moiety, in modulating the conformational rearrange-
ments of the dimer interface(s).
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Atypical antipsychotic drugs targeting the 5-HT2A receptor (2AR) are widely
used in the treatment of schizophrenia and psychosis. Recent studies point to a
new class of potential antipsychotic drugs targeting the metabotropic glutamate
receptor 2 (mGluR2). We recently reported that a heteromeric complex formed
between these two receptors integrates the actions of serotonergic and glutama-
tergic drugs, modulating the balance between Gi and Gq signaling in a way that
can predict the psychoactive properties of these drugs (Fribourg et al. 2011,
Cell. 147(5):1011-23). The biological relevance of the mGluR2/2AR crosstalk
was challenged by a more recent study in which co-expression of the two re-
ceptors in HEK-293 cells had no significant effect on either Gi or Gq signaling
in response to several serotonergic and glutamatergic drugs (Delille et al.,
2012, Neuropharmacology 62(7):2184-91). To address this controversy, we
generated several clones of HEK-293 cells expressing different levels of the
two receptors in the background of the G protein inwardly rectifying
GIRK1/GIRK4 channel, which can serve as a reporter for both Gi and Gq
signaling. Using the ratiometric calcium indicator Fura-2 for quantification
of Gq signaling we identified clones showing various degrees of functional
crosstalk between the two receptors (crosstalk positive clones) and clones
that were crosstalk negative. Functional crosstalk correlated with the expres-
sion levels of the two receptors, as measured by real time RT-PCR and flow-
cytometry. GIRK channel activity, measured by electrophysiology, confirmed
cross-signaling from both Gi and Gq sides in a crosstalk positive clone, but not
a crosstalk negative one. In the later, a combination of ligands targeting both
receptors was necessary in order to elicit functional crosstalk. We are currently
testing positive allosteric modulators of the mGluR2 for their ability to sup-
press Gq signaling through 2AR.
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Atypical antipsychotic drugs targeting the Gq-coupled serotonin 5-HT2A re-
ceptor (2AR) are widely used in the treatment of schizophrenia, whereas recent
studies point to a new class of potential antipsychotic drugs targeting the Gi-
coupled metabotropic glutamate 2 receptor (mGluR2). A physical and func-
tional interaction between the two receptors in cortical pyramidal neurons
has been demonstrated.
Using heterologously expressed receptors in Xenopus oocytes, we have previ-
ously shown that the heteromeric mGluR2/2AR complex integrates the actions
of serotonergic and glutamatergic ligands, modulating the balance between Gi
and Gq signaling in a way that can be used to predict the psychoactive proper-
ties of these drugs.
Selective positive allosteric modulators (PAMs) of mGluR2 that bind to the
transmembrane region of the receptor have shown efficacy in rodent models
predictive of antipsychotic activity. Here we show that the mGluR2 PAM,
LY487379 (or simply LY48) not only enhances glutamate-induced Gi
signaling but also shows crosstalk by reducing 5-HT-induced Gq signaling.
PAMs offer a promising therapeutic approach for the activation of GPCRs
because they preserve the physiologic pattern of receptor signaling and are
less likely to cause receptor desensitization and/or down regulation than syn-
thetic agonists.
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Metabotropic glutamate receptors (mGluRs) are G-protein coupled receptors
that are found throughout the nervous system where they respond to the major
excitatory neurotransmitter, glutamate, to modulate synaptic transmission and
plasticity via a variety of effectors. mGluRs are characterized by obligate
dimerization and the presence of large extracellular ligand binding domains.
In this study we used a combination of novel optical techniques to examine
